Burris, Howard A. III
Kurkjian, C. D.
Hart, L.
Pant, S.
Murphy, P. B.
Jones, S. F.
Neuwirth, R.
Patel, C. G.
Zohren, F.
Infante, J. R.
Funding for this research was provided by:
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 3 May 2017
Accepted: 20 May 2017
First Online: 10 June 2017
Compliance with ethical standards
:
: This study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
: HA Burris, S Pant, PB Murphy, and SF Jones disclose no potential conflicts of interest. CD Kurkjian participated in an advisory board meeting for Halozyme Therapeutics Inc. (consultant/advisory role). L Hart discloses research funding to institution from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. JR Infante discloses participation in a consultant/advisory role for Takeda on behalf of institution. R Neuwirth, CG Patel, and F Zohren are employees of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. CG Patel and F Zohren also disclose stock ownership (Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited).
: The study was approved by the institutional review board at each site and conducted per the Declaration of Helsinki, the International Conference on Harmonisation, and Good Clinical Practice guidelines. All patients provided written informed consent.